Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals has demonstrated a strong financial performance, generating $316 million in precision medicine revenue in the second half of 2025, with a notable 4% quarter-over-quarter growth attributed to successful sales in the U.S. The company’s promising pipeline, particularly with the potential expansion into prostate cancer diagnosis, could significantly increase the total addressable market by approximately $3.5 billion, providing substantial growth opportunities. Additionally, Telix's achievement of 2025 revenue targets underscores its effective execution and robust commercial performance, warranting a favorable outlook for the company’s stock.

Bears say

Telix Pharmaceuticals has reported a net loss of $1.0 million with an earnings per share (EPS) of $(0.30), surpassing both internal estimates and consensus but still indicating ongoing financial difficulties. The company faces multiple risks, including potential negative clinical results for its lead asset TLX591, delays in pipeline development, and regulatory challenges that may hinder its operations and revenue generation. Additionally, financial stability is threatened by balance sheet and liquidity risks, competition in the radiopharmaceutical market, and long-term dilution concerns, which collectively contribute to a negative outlook on the stock.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.